Back to The Past: The Case for Improving Upon, Not Throwing Out Traditional Cancer Phase I Study Designs
Executive Summary
US FDA has pushed sponsors away from the traditional dose-finding designs for cancer drugs in recent years. But academics continue to make a case for keeping the 3+3 design with some improvements.